OneSource Specialty Pharma Limited announced strong financial performance for the fourth quarter and full year ended March 31, 2026, driven by broad-based business momentum and commercial launches of semaglutide products in India.

For Q4 FY26, the company reported revenues of Rs. 4,282 million, reflecting a 47% quarter-on-quarter increase. The growth was supported by expansion across all service offerings and the commercial launch of semaglutide in India.

EBITDA for the quarter stood at Rs. 919 million, registering more than fivefold growth sequentially, driven by operating leverage on higher CSA revenues. Adjusted profit after tax (PAT) stood at Rs. 390 million, while adjusted earnings per share (EPS) was Rs. 3.4.

The company also reaffirmed its FY28 guidance, targeting approximately US$ 400 million in organic revenue with EBITDA margins of around 40%.

Commenting on the performance, Neeraj Sharma, CEO & Managing Director of OneSource Specialty Pharma Limited, said the company witnessed a strong recovery in Q4 supported by broad-based business performance.

He noted that the quarter was marked by successful semaglutide launches in India across multiple customer brands, along with new launches in the U.S. injectables and soft-gelatin businesses.

Sharma added that recent semaglutide approvals in Canada and continued expansion of the company’s biologics pipeline position OneSource Specialty Pharma for sustained growth momentum in FY27.